Prevalence of hepatitis B virus infection among individuals with active tuberculosis attending selected Directly Observed Therapy (DOT) clinics in Oyo State, Nigeria Authors: Adeola D Ayanyinka, Itunuoluwa C Oyelayo, Habeeb O Abiona, Fiyinfoluwa Demilade Ojeniyi, Oluyinka O Opaleye, Olusola Ojurongbe, Olugbenga A Olowe Published: 2025 ABSTRACT AbstractBackgroundHepatitis B virus (HBV) remains a major public health concern, particularly in low- and middle-income countries like Nigeria. In sub-Saharan Africa, the convergence of HBV and tuberculosis (TB) presents a dual epidemic, complicating disease management due to the hepatotoxic nature of anti-TB therapy. This study aimed to determine the prevalence of HBV infection and associated liver dysfunction among individuals infected with tuberculosis in Oyo State, Nigeria.MethodsA cross-sectional study was conducted from February 2024 to August 2024 among 216 individuals infected with TB attending selected DOT clinics in Oyo state, Nigeria. Participants were screened for HBV using the HBV-5 panel rapid diagnostic kit. Liver function was evaluated via serum liver enzymes using the Randox Kit. HBsAg-positive samples were further tested for HBV-DNA using nested PCR targeting the S and P gene of the HBV genome. All socio-demographic, clinical and serological data were analyzed using SPSS version 25.0. Associations between variables and HBsAg positivity were assessed analyzed using univariable and multivariable logistic regression methods. A p-value of < 0.05 was considered statistically significant.ResultsThe overall prevalence of HBV (HBsAg) was 11.6% (25/216), highest in the 30–44 age groups (4.6%). Among males (n = 128), 14 (6.5%) were HBsAg-positive, while females (n = 88), 11 (5.1%) were positive. Significant associations were found with household history of hepatitis (p = 0.006), body tattoos (p = 0.043), body piercing (p = 0.035), and smoking (p = 0.041). HBV-DNA was detected in 64.0% (16/25) of HBsAg-positive individuals, despite universal HBeAg negativity. Among the HBsAg-positive cases, 48.0% had elevated AST, while ALT remained normal. Elevated conjugated bilirubin was observed in 52.0%, and total bilirubin in 4.0%.ConclusionA notable burden of active HBV infection and liver dysfunction exists among individuals infected with tuberculosis. Routine HBV screening and liver function monitoring should be integrated into TB care. Further studies on occult HBV infection, genotyping, and longitudinal liver assessments are recommended.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12171-z.Keywords: Hepatitis B virus, Tuberculosis, Co-infection, HBV-DNA, Liver dysfunction, Nigeria Introduction Co-infection with tuberculosis and hepatitis B virus is an emerging clinical and public health concern, particularly in regions where both pathogens are highly endemic, such as sub-Saharan Africa [1]. Tuberculosis is ranked among the top 10 causes of death globally and the leading cause of death from a single infectious disease agent [2]. In 2022, there were 7.5 million newly diagnosed cases of tuberculosis worldwide, the largest number of cases reported in a single year since WHO began monitoring tuberculosis globally in the mid-1990s and 1.30 million recorded death cases. Nigeria ranks sixth among the 30 high TB burden countries, contributing 4.6% to the global burden and has the highest burden in Africa [2]. Middle-income nations like Nigeria have higher rates of the disease because of factors like poverty, unhealthy lifestyles, a high rate of HIV infection, inadequate early TB screening, and delayed treatment with approved anti-TB medications [3]. In Nigeria, HBV is highly endemic with an estimated 13.6% of its population infected, contributing significantly to the 75 million HBV cases across Africa [4]. About 90% of Nigerians with chronic HBV are unaware of their status, mainly due to limited resources, low awareness, and insufficient public health prioritization [5]. HBV infection can lead to various liver diseases, including acute and chronic hepatitis, cirrhosis and liver failure [6]. Reported prevalence of hepatitis B virus infection among tuberculosis cases varies considerably worldwide, ranging from 0.5% to 44% across different geographic regions, with the highest rates observed in Africa according to recent systematic reviews [7, 8]. In Nigeria, the prevalence varies considerably by location and study, with recent reports indicating rates between 8% and 15% [9–12]. HBV-TB coinfection significantly complicates the effective treatment of tuberculosis, as both infections affect liver function and share similar clinical symptoms such as fatigue and liver enlargement as reported in both local and international studies [12, 13]. First-line anti-TB drugs like isoniazid, rifampicin, and pyrazinamide are known to cause hepatotoxicity, and their effects are exacerbated in the presence of chronic HBV infection. This dual impact on the liver heightens the risk of drug-induced liver injury (DILI), manifesting in elevated liver enzymes, abnormal bilirubin levels, and, in severe instances, acute hepatic failure. Such complications often result in delayed or discontinued treatment, reduced patient compliance, and increased rates of morbidity and mortality [14]. Despite the clinical risks of HBV-TB co-infection, routine HBV screening among TB patients remains limited, and standardized management protocols are lacking. Addressing this gap is critical to improve detection, optimize care, and reduce adverse treatment outcomes. This study aimed to assess the prevalence of HBV infection and liver dysfunction among individuals with tuberculosis attending DOT clinics in Oyo state, Nigeria. Materials and methods Study setting, design and population This study was conducted across selected Directly Observed Therapy (DOT) clinics in various local government areas of Oyo State, Southwestern Nigeria. A cross-sectional design was adopted to evaluate consenting individuals with clinically and laboratory-confirmed tuberculosis who were receiving treatment at the participating DOT centers. Data collection was conducted over six-months, from February to August 2024. The sample size was calculated using a prevalence estimate of 14.9% for HBV among individuals infected with TB, as reported by Imoru et al. (2018). Incorporating a 10% margin for potential non-responses, a total of 216 participants were recruited. Information on socio-demographic variables, clinical history, and behavioral risk factors was obtained using structured, interviewer-administered questionnaires, with support from trained healthcare workers operating within the DOT facilities. Blood samples collection and serological testing Five milliters of venous blood were collected into serum-separating tubes, centrifuged at 3000 rpm for five minute and the serum was subsequently used for analysis. HBV serological markers (HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb) were detected using the HBV 5-panel rapid test kit (Solid Diagnostics, China). HBsAg-positive samples were assayed for liver function markers, including ALT, AST, total and conjugated bilirubin, using Randox diagnostic reagents (Randox Laboratories Ltd., UK), following the manufacturer’s guidelines. Genomic DNA extraction DNA was extracted from serum samples that tested positive for HBsAg using the QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany). Protease and lysis buffer were applied to 200 µL of serum, followed by two sequential wash steps. DNA was eluted in 50 µL of elution buffer and stored at − 20 °C until further analysis. Molecular detection of HBV-DNA The presence of HBV DNA in HBsAg-positive samples was confirmed using nested polymerase chain reaction (PCR) targeting conserved regions of the S and P genes of the HBV genome. DNA amplification was performed to enhance detection sensitivity and specificity. Primers used for both PCR rounds were synthesized by Inqaba Biotechnical Industries Ltd. (Pretoria, South Africa), and the primer sequences were adopted as previously described [15]. In the first-round PCR, outer primers HBPr134 (5’-TGCTGCTATGCCTCATCTTC-3’) and HBPr135 (5’-CAGAGACAAAAGAAAATTGG-3’) were used. Each 20 µL reaction mixture contained 10x PCR buffer, 25 mM MgCl₂, 20 mM dNTPs, 0.5 µL each of the forward and reverse primers, 0.2 µL of Taq polymerase, 5 µL of DNA template, and nuclease-free water to volume. Thermal cycling was performed on an Eppendorf ™ Mastercycler X50 thermal cycler with the following conditions: initial denaturation at 94 °C for 2 min; 35 cycles of denaturation at 94 °C for 30 s, annealing at 52 °C for 30 s, and extension at 72 °C for 45 s; followed by a final extension at 72 °C for 5 min. A second-round (nested) PCR was conducted using 3 µL of the first-round product as template, with inner primers HBPr75 (5’-CAAGGTTATGTTGCCCGTTTGTCC-3’) and HBPr94 (5’-GGTATAAAGGGACTCACGATG-3’). The thermal cycling conditions remained the same, with the cycle number increased to 40 for enhanced sensitivity. Positive (HBV plasmid DNA) and negative (nuclease-free water) controls were included in each run. PCR products were separated on a 1.5% agarose gel stained with ethidium bromide and visualized on a Gel documentation system (Azure 200, Dublin, CA). A distinct 340 bp band confirmed the presence of HBV DNA. Statistical analysis Data from the investigation were analyzed using IBM SPSS version 25.0. Categorical variables were compared using the Chi-square test or Fisher’s exact test, where appropriate, with a 95% confidence interval. Binary logistic regression was performed to determine the association between selected risk factors and HBsAg positivity, with results reported as odds ratios (ORs) and 95% confidence intervals (CIs). Both crude and adjusted ORs were calculated. Statistical significance was set at p < 0.05. Results Socio-demographic characteristics of study participants A total of 216 individuals with active tuberculosis were enrolled across selected DOT clinics in Oyo State, Nigeria. The mean age of participants was 38 years (range: 18–70 years). As shown in Table 1, the largest age group was 30–44 years (48.1%), followed by 45–59 years (31.0%), while only 4.2% were aged 60 years and above. Table 1Socio-demographic characteristics of individuals with tuberculosis in Oyo state, Nigeria (n = 216)VariablesCategoriesFrequency (n)Percent (%)Age Group18–293616.730–4410448.145–59673160- above94.2GenderMale12859.3Female8840.7Marital StatusSingle6329.2Married14567.1Separated52.3Divorced10.5Widowed20.9ReligionChristian11553.2Muslim10146.8Level Of EducationPrimary3717.1Secondary12859.3Tertiary5123.6OccupationMedical Practitioner62.8Civil Servant209.3Trader6429.6Artisan3114.4Others9544ResidenceUrban6831.5Rural14868.5 Socio-demographic characteristics of individuals with tuberculosis in Oyo state, Nigeria (n = 216) Males represented 59.3% (n = 128) of the study population, while females accounted for 40.7% (n = 88). Most participants were married (67.1%), with 29.2% single, 2.3% separated, 0.5% divorced, and 0.9% widowed. With respect to religion, 53.2% were Christians and 46.8% Muslims. With respect to educational attainment, secondary education constituted the highest level achieved by most participants (59.3%), followed by tertiary (23.6%) and primary (17.1%) levels. Occupationally, traders (29.6%) formed the largest group, followed by artisans (14.4%), civil servants (9.3%), and medical practitioners (2.8%). Other unspecified occupations made up 44.0% of the respondents. A majority of participants resided in rural areas (68.5%), while 31.5% lived in urban settings. Prevalence of HBV serological markers As presented in Table 2, the overall prevalence of HBsAg among individuals with tuberculosis was 11.6% (25/216). The HBcAb (total anti-HBc) marker was detected in 16.7% (36/216) of participants, while HBsAb was found in 9.3% (20/216). HBeAb was detected in 11.1% (24/216), whereas no participant tested positive for HBeAg (0.0%). Table 2Prevalence of HBV serological markers among individuals with tuberculosis in Oyo state, Nigeria (n = 216)VariableFrequency (n)Percentage (%)HBsAg2511.6HBcAb (total Anti-HBc)3616.7HBeAg00.0HBeAb2411.1HBsAb209.3 Prevalence of HBV serological markers among individuals with tuberculosis in Oyo state, Nigeria (n = 216) Clinical risk factors associated with HBsAg positivity The distribution of clinical risk factors in relation to HBsAg positivity is presented in Table 3. A statistically significant association was found between household history of hepatitis and HBsAg positivity in the univariate analysis (p = 0.006). However, this relationship lost significance in multivariate analysis (p = 1.000), likely due to the limited number of participants with a documented family history. No statistically significant associations were observed between HBsAg positivity and history of blood transfusion, previous surgery, hospital admission, unsafe abortion, intravenous drug use, unsafe injection practices, traditional tooth extraction, history of sexually transmitted infection (STI), previous HBV infection, or HBV vaccination (p > 0.05). Only 4 participants (1.9%) reported receiving HBV vaccination, while none of the vaccinated participants were HBsAg positive. Table 3Clinical risk factors associated with HBsAg positivity among individuals infected with TB attending DOT clinics in Oyo State, Nigeria: univariate and multivariate analysis (n = 216)Risk FactorsCategoryFrequencyHBsAg+Crude OR (95%CI)P-valueAdjusted OR (95%CI)P-valueHistory of Blood TransfusionNo199(92.1%)24(12.1%)11Yes17(7.9%)1(5.9%)0.46(0.58–3.59)0.4560.48(0.05–4.85)0.533Previous SurgeryNo211(97.7%)25(11.8%)11Yes5(2.3%)0(0.0%)0.00(0.00)0.9990.00(0.00)0.999Household History of HepatitisNo215(99.5%)24(11.2%)11Yes1(0.5%)1(100.0%)0.13(0.00)0.0060.00(0.00)1.000Recent Hospital AdmissionNo158(73.1%)16(10.1%)11Yes58(26.9%)9(15.5%)0.61(0.26–1.48)0.2762.73(0.94–7.95)0.066Unsafe Abortion (female participants)No108(50.0%)13(12.0%)11Yes8(3.7%)0(0.0%)0.00(0.00)0.9990.00(0.00)0.999Intravenous Drug UseNo211(97.7%)24(11.1%)11Yes5(2.3%)1(0.5%)0.51(0.05–4.78)0.5580.26(0.01–5.82)0.397Unsafe InjectionNo206(95.4%)24(11.1%)11Yes10(4.6%)1(0.5%)1.18(0.14–9.78)0.8741.46(0.08–26.93)0.796Traditional Tooth ExtractionNo208(96.3%)24(11.5%)11Yes8(3.7%)1(12.5%)1.10(0.13–9.29)0.9340.75(0.70–8.12)0.814History of STINo199(92.1%)23(11.6%)11Yes17(7.9%)2(11.8%)1.02(0.21–4.75)0.9800.50(0.52–4.84)0.550Previous HBV InfectionNo214(99.1%)25(11.7%)11Yes2(0.9%)0(0.0%)0.00(0.00)0.9990.00(0.00)0.999HBV VaccinationNo212(98.1%)25(11.8%)11Yes4(1.9%)0(0.0%)0.00(0.00)0.9990.00(0.00)0.999Crude OR - Crude Odd RatioAdjusted OR - Adjusted Odd RatioCI- Confidence Interval Clinical risk factors associated with HBsAg positivity among individuals infected with TB attending DOT clinics in Oyo State, Nigeria: univariate and multivariate analysis (n = 216) Crude OR - Crude Odd Ratio Adjusted OR - Adjusted Odd Ratio CI- Confidence Interval Socio-behavioral risk factors associated with HBsAg positivity The association between socio-behavioral characteristics and HBsAg positivity is shown in Table 4. After adjusting for potential confounders, three variables demonstrated statistically significant associations with HBsAg positivity: body tattoo (aOR = 1.07; p = 0.043), body piercing (aOR = 3.20; p = 0.035) and smoking (aOR = 3.30; p = 0.041). The frequency distribution further indicates that participants with tattoos or piercings accounted for 17.1% and 18.1% of the total population respectively, and had proportionally higher HBsAg positivity rates than those without such practices. Other risk factors, including needle sharing, toothbrush sharing, multiple sexual partners, condom use, homosexual intercourse, alcohol consumption, and contact with HBV-infected individuals, did not show statistically significant associations (p > 0.05). Table 4Socio-Behavioral risk factors associated with HBsAg positivity among individuals infected with TB attending DOT clinics in Oyo state, Nigeria. Univariate and multivariate analysis (n = 216)Risk FactorsCategoryFrequencyHBsAg+Crude OR (95%CI)P-valueAdjusted OR (95%CI)P-valueNeedle SharingNo208(96.3%)24(11.5%)11Yes8(3.7%)1(12.5%)1.10(0.13–9.30)0.9341.14(0.08–16.07)0.925History of toothbrush sharingNo209(96.8%)24(11.1%)11Yes7(3.2%)1(0.5%)0.77(0.09–6.74)0.821.06(0.05–19.92)0.969Body tattooNo179(82.9%)18(10.1%)11Yes37(17.1%)7(18.9%)2.09(0.80–5.42)0.1311.07(0.30–3.81)0.043Body piercingNo177(81.9%)18(10.2%)11Yes39(18.1%)7(17.9%)1.93(0.75–5.01)0.1753.20(1.08–9.47)0.035Multiple Sexual PartnersNo154(71.3%)18(11.7%)11Yes62(28.7%)7(11.3%)0.96(0.38–2.43)0.9340.57(0.15–2.25)0.422Lifetime Sexual Partners0–2166(76.9%)18(10.8%)113–544(20.4%)5(11.4%)0.24(0.04–1.42)0.1171.37(0.35–5.40)0.655> 56(2.8%)2(33.3%)0.26(0.03–1.77)0.1682.92(0.28–30.51)0.369Condom Use (Last Intercourse)No90(41.7%)11(12.2%)11Yes126(58.3%)14(11.1%)0.90(0.39–2.08)0.8011.03(0.40–2.63)0.958Homosexual IntercourseNo208(96.3%)24(11.5%)11Yes8(3.7%)1(12.5%)1.10(0.13–9.30)0.9342.34(0.91–28.71)0.505Contact with HBV infected person(s)No213(98.6%)25(11.7%)11Yes3(1.4%)0(0.0%)0.00(0.00)0.9990.00(0.00)0.999SmokingNo170(78.7%)17(10.0%)11Yes46(21.3%)8(17.4%)1.90(0.76–4.72)0.1703.30(1.05–10.41)0.041Alcohol consumptionNo132(61.1%)16(12.1%)11Yes84(38.9%)9(10.7%)0.87(0.36–2.07)0.7530.59(0.20–1.71)0.332Crude OR - Crude Odd RatioAdjusted OR - Adjusted Odd RatioCI- Confidence Interval Socio-Behavioral risk factors associated with HBsAg positivity among individuals infected with TB attending DOT clinics in Oyo state, Nigeria. Univariate and multivariate analysis (n = 216) Crude OR - Crude Odd Ratio Adjusted OR - Adjusted Odd Ratio CI- Confidence Interval Molecular detection of HBV DNA in HBsAg-positive participants Nested PCR assay confirmed the presence of HBV DNA in 64.0% (16/25) of the HBsAg-positive samples, confirming the presence of active viral replication. The remaining 9 samples (36.0%) were negative for HBV DNA. The amplified products yielded the expected 340 bp band corresponding to the targeted region of the HBV genome. Figure 1 shows a representative agarose gel electrophoresis image illustrating the presence of this band in positive samples. Representative agarose gel electrophoresis of PCR products for HBV DNA detection in HBsAg-positive TB participants Lane M: 100 bp molecular weight marker; Lane 1: Positive control; Lane 19: Negative control. Lanes 4, 9 and 14 were negative for HBV DNA, while all other lanes show positive amplification. Liver enzyme and bilirubin profiles in HBsAg-positive TB participants Assessment of hepatic function among HBsAg-positive individuals is summarized in Table 5 and illustrated in Fig. 2. Elevated AST levels were observed in 12 participants (48.0%), while ALT levels remained within normal limits across all cases (100%). Conjugated bilirubin was elevated in 52.0%wheres total bilirubin was elevated in 4.0% of the HBsAg-positive participants. None of these variations showed statistical significance (p > 0.05). Table 5Liver enzyme and bilirubin levels among HBsAg-Positive TB patients (n = 25)Liver EnzymesLiver Enzyme Levelp-valueNormalElevatedAST13(52.0%)12(48.0%)0.120ALT25(100%)0(0.0%)-Total Bilirubin24(96.0%)1(4.0%)0.290Conjugated Bilirubin12(48.0%)13(52.0%)0.200Normal range of liver enzymesAST: (5–40 U/L)ALT: (4–36.0 U/L)Bilirubin total: (2–17 µmol/L)Bilirubin Conjugated: (0–5.1 µmol/L)AST- aspartate aminotransferaseALT- alanine aminotransferaseTB - total bilirubinCB - conjugated bilirubin Liver enzyme and bilirubin levels among HBsAg-Positive TB patients (n = 25) Normal range of liver enzymes AST: (5–40 U/L) ALT: (4–36.0 U/L) Bilirubin total: (2–17 µmol/L) Bilirubin Conjugated: (0–5.1 µmol/L) AST- aspartate aminotransferase ALT- alanine aminotransferase TB - total bilirubin CB - conjugated bilirubin Distribution of liver enzyme and bilirubin levels among HBsAg-positive TB participants Discussion In this study, the prevalence of HBsAg among individuals infected with tuberculosis was 11.6%, indicating high HBV endemicity according to WHO classification (>8%) [16]. This finding is consistent with a recent report from Kwara State (10.5%) [10], but higher than rates reported in Jos (5.6%) [11] and a pooled review (9.5%) [17]. However, it is lower than the 14.9% reported in Sokoto [9]. A cross-country comparison shows that the rate observed in this study exceeds that of Ethiopia (3.4%) [18] and Sudan (9.5%) [19], but remains below the 25.6% reported in Brazil [20]. These prevalence differences may be attributed to variations in diagnostic methods, sample size, geography, and population-specific risk exposures [18]. The 30–44-year age group had the highest HBV prevalence (4.6%), echoing similar trends reported in Romania [21]. Though not statistically significant, males showed higher HBsAg positivity, consistent with national data linking male practices such as circumcision and use of shared sharp instruments to increased risk [22]. Married individuals also had higher prevalence, possibly due to unprotected sexual contact [23]. In this study, household history of hepatitis, body tattoos, piercings, and smoking were statistically significant associations with HBV positivity. Similar associations have been reported in Ethiopia, Egypt, and other settings [24–26]. Household history of hepatitis may reflect repeated exposure to infected family members and serves as a possible route for both vertical and horizontal HBV transmission, particularly in settings with shared items or inadequate infection-control practices [27]. However, the specific family member who was HBV-positive was not documented. Body modification practices such as tattooing and piercing breach the skin barrier and are recognized routes for blood-borne pathogen transmission, particularly when non-sterile instruments or unregulated procedures are involved. Several studies and reviews have demonstrated a consistent association between these practices and HBV infection, including outbreaks and elevated seroprevalence among individuals with tattoos or piercings [24–26, 28]. Smoking may indirectly increase infection risk by impairing immune response and reducing vaccine efficacy, as evidenced by studies linking tobacco use to lower post-vaccination anti-HBs titers [29, 30]. Other exposures that did not reach statistical significance such as history of blood transfusion, prior surgery and multiple sexual partners were still observed at relatively high frequencies and remain biologically plausible routes of HBV acquisition. Blood transfusion and invasive procedures continue to pose risks in regions where screening or infection-control measures are suboptimal [31], while sexual contact remains a major source of adult HBV transmission globally [32]. These frequent but non-significant exposures warrant consideration as potential contributors to community transmission. These findings highlight the importance of maintaining sterile and safe practices and strengthening public health education to reduce HBV transmission risks. The presence of HBsAb in 9.3% of HBsAg-negative individuals indicates prior vaccination or natural immunity. None of the participants tested positive for HBeAg, suggesting low viral replication [33]. HBeAb positivity (11.1%) implies reduced infectivity. HBcAb was detected in 16.7%, which indicates that a significant proportion of the participants had been exposed to HBV at some point, it’s presence in HBsAg-negative individuals may indicate a resolved HBV infection or occult HBV infection (OBI) where the virus persists at low levels despite the absence of detectable HBsAg [34]. Vaccination coverage in this study was notably low (1.9%), which may contribute to the continued transmission of HBV among individuals with tuberculosis. This rate is substantially lower than the 17.4% coverage previously reported in Northern Nigeria [35] and may reflect regional disparities in awareness or access to vaccination services [36]. Although the exact timing of vaccination could not be ascertained, the few vaccinated participants reported receiving the adult catch-up series (a full three-dose schedule) rather than the infant birth-dose schedule. The limited uptake underscores the need to strengthen HBV vaccination coverage and awareness in this population, particularly through targeted catch-up programs for adults and high-risk groups, in alignment with current WHO and national immunization recommendations [37]. Furthermore, novel vaccine technologies particularly circular RNAs (circRNAs) platforms are being explored and could provide additional options for HBV prevention in the future. CircRNAs vaccines form a closed-loop structure, making them naturally more stable and less susceptible to enzymatic breakdown than conventional linear mRNA vaccines [38]. This improved stability can support prolonged antigen expression, potentially reduce the number of doses required, and ease handling and storage demands, including reduced dependence on strict cold-chain systems [39]. Although circRNAs-based vaccines are still in early development, their potential benefits make them a promising option for enhancing HBV immunization, especially in regions where logistical barriers limit vaccine delivery [40]. HBV DNA was detected in 64% of HBsAg-positive participants, confirming active replication. This finding underscores the risk of liver injury in co-infected individuals undergoing anti-TB therapy [41, 42]. The remaining 36% were DNA-negative, likely representing inactive carriers or occult infections [43, 44]. HBsAg remains the principal marker for determining current HBV infection status, while HBV DNA quantification provides a more direct measure of viral replication and infectivity. The inclusion of anti-HBc aids in distinguishing previous exposure from active infection, whereas HBeAg and anti-HBe profiles serve as indicators of viral replication phase and immune control [45]. In this study, the combination of serological markers and molecular detection improved diagnostic accuracy and reduced the likelihood of misclassification. This integrated diagnostic approach aligns with current global recommendations for accurate characterization of HBV infection status among co-infected populations [46]. Elevated AST levels were observed in 48% of HBsAg-positive cases, while ALT levels remained within the normal range across all cases. Mild increases in conjugated (52%) and total bilirubin (4%) were also observed but were not statistically significant. The predominance of AST elevation with normal ALT is atypical for viral hepatitis, where ALT usually predominates [47]. The pattern observed in this study may indicate mild hepatocellular stress, extra-hepatic enzyme contribution or transient drug-related effects [48–50]. The standard treatment for newly diagnosed TB cases consists of a six-month regimen involving four medications: isoniazid, rifampicin, ethambutol, and pyrazinamide, of which isoniazid, rifampicin, and pyrazinamide are known to be hepatotoxic and may cause drug-induced liver injury (DILI) [51]. In this study, all participants had received anti-TB therapy for at least two months before the screening exercise, which may have contributed to the observed enzyme elevations. However, other potential causes such as underlying HBV infection, metabolic liver changes, alcohol intake, or metabolic dysfunction-associated fatty liver disease (MAFLD) cannot be excluded without further evaluation, which would require serial liver tests, CK, GGT/ALP, HBV viral load assessment and imaging or histology where indicated [52, 53]. These findings highlight the need for comprehensive evaluation, including viral load testing, lifestyle assessment and liver biopsy, in order to ascertain the causes of hepatic abnormalities in TB cases with HBV co-infection. Severe complications may occur in individuals on anti-TB therapy with chronic HBV co-infection, including liver injury, cirrhosis, hepatic failure, poor treatment outcomes and increased mortality [13, 54]. The hepatotoxic effects of anti-TB drugs can further exacerbate underlying liver disease, resulting in treatment interruption or hepatic decompensation. Furthermore, HBV/TB co-infection may aggravate disease progression, trigger reactivation of latent infections, and increase the risk of complications during immunologically sensitive conditions such as pregnancy [55]. These risks highlight the need for routine HBV screening and vigilant hepatic monitoring during TB management. Limitations of the study This study has certain limitations that is noteworthy for discussion. The sample size was relatively limited, which may have reduced the statistical power to detect weaker associations between HBV infection and potential risk factors. The timing and completion of HBV vaccination could not be verified, although all self-reported vaccinated individuals showed serological patterns consistent with vaccine-induced immunity. Assessment of hepatic function was limited to serum enzyme and bilirubin measurements without imaging or histological confirmation. Consequently, the observed hepatic alterations could not be conclusively attributed to anti-tuberculosis therapy alone, as other underlying or coexisting factors may have contributed to liver dysfunction. These limitations should be taken into account when interpreting the study findings. Conclusion This study underscores the clinical and public health importance of HBV–TB co-infection in Nigeria. The detection of active HBV replication among individuals with tuberculosis highlights a potential risk for hepatic complications during anti-TB therapy. Our findings emphasize the need for integrated HBV screening, improved vaccination coverage and closer monitoring of liver function within TB management programs to enhance treatment safety and mitigate the burden of co-infection in this population. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We gratefully acknowledge the support provided by the Tertiary Education Trust Fund (TETFUND) and the Humboldt Research Hub, Center for Emerging and Reemerging Infectious Diseases, Ladoke Akintola University of Technology. Their valuable contributions significantly facilitated the success of this research. Abbreviations Hepatitis B Virus Human Immunodeficiency Virus Directly Observed Therapy Tuberculosis Hepatitis B Surface Antigen Hepatitis B Virus Deoxyribonucleic Acid Aspartate Aminotransferase Alanine Aminotransferase Hepatitis B Core Antibody Hepatitis B e Antibody Hepatitis B e Antigen Hepatitis B Surface Antibody Author contributions OAO, ICO, and OAO conceptualized and designed the study. OAO, ICO, and HOA conducted the experimental work and drafted the manuscript. ADA and FDO performed the data analysis. All authors contributed to data interpretation, and all have reviewed and approved the final manuscript. Funding The authors declare that there was no funding for this study. Data availability The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki (2024). Ethical approval was obtained from the Oyo State Ministry of Health Research Ethics Committee (NREC No: NHREC/OYOSHRIEC/10/11/22), along with administrative clearance from relevant district health authorities. Informed consent was obtained from all participants or their legal guardians before data collection. Participation was entirely voluntary, and confidentiality was ensured through the use of coded identifiers. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.